S&P 500   3,852.50 (-0.46%)
DOW   31,445.44 (+0.17%)
QQQ   313.52 (-1.53%)
AAPL   123.98 (-0.91%)
MSFT   229.89 (-1.70%)
FB   257.60 (-0.54%)
GOOGL   2,038.20 (-1.27%)
TSLA   679.98 (-0.94%)
AMZN   3,041.93 (-1.70%)
NVDA   520.79 (-2.88%)
BABA   237.43 (+1.28%)
CGC   33.80 (-4.11%)
GE   13.42 (+3.39%)
MU   90.62 (-0.52%)
NIO   42.90 (-0.90%)
AMD   82.44 (-2.01%)
T   28.51 (+1.03%)
F   12.27 (-2.23%)
ACB   10.59 (-3.99%)
DIS   194.13 (+0.10%)
BA   232.12 (+4.02%)
NFLX   528.02 (-3.61%)
PFE   34.00 (+1.46%)
S&P 500   3,852.50 (-0.46%)
DOW   31,445.44 (+0.17%)
QQQ   313.52 (-1.53%)
AAPL   123.98 (-0.91%)
MSFT   229.89 (-1.70%)
FB   257.60 (-0.54%)
GOOGL   2,038.20 (-1.27%)
TSLA   679.98 (-0.94%)
AMZN   3,041.93 (-1.70%)
NVDA   520.79 (-2.88%)
BABA   237.43 (+1.28%)
CGC   33.80 (-4.11%)
GE   13.42 (+3.39%)
MU   90.62 (-0.52%)
NIO   42.90 (-0.90%)
AMD   82.44 (-2.01%)
T   28.51 (+1.03%)
F   12.27 (-2.23%)
ACB   10.59 (-3.99%)
DIS   194.13 (+0.10%)
BA   232.12 (+4.02%)
NFLX   528.02 (-3.61%)
PFE   34.00 (+1.46%)
S&P 500   3,852.50 (-0.46%)
DOW   31,445.44 (+0.17%)
QQQ   313.52 (-1.53%)
AAPL   123.98 (-0.91%)
MSFT   229.89 (-1.70%)
FB   257.60 (-0.54%)
GOOGL   2,038.20 (-1.27%)
TSLA   679.98 (-0.94%)
AMZN   3,041.93 (-1.70%)
NVDA   520.79 (-2.88%)
BABA   237.43 (+1.28%)
CGC   33.80 (-4.11%)
GE   13.42 (+3.39%)
MU   90.62 (-0.52%)
NIO   42.90 (-0.90%)
AMD   82.44 (-2.01%)
T   28.51 (+1.03%)
F   12.27 (-2.23%)
ACB   10.59 (-3.99%)
DIS   194.13 (+0.10%)
BA   232.12 (+4.02%)
NFLX   528.02 (-3.61%)
PFE   34.00 (+1.46%)
S&P 500   3,852.50 (-0.46%)
DOW   31,445.44 (+0.17%)
QQQ   313.52 (-1.53%)
AAPL   123.98 (-0.91%)
MSFT   229.89 (-1.70%)
FB   257.60 (-0.54%)
GOOGL   2,038.20 (-1.27%)
TSLA   679.98 (-0.94%)
AMZN   3,041.93 (-1.70%)
NVDA   520.79 (-2.88%)
BABA   237.43 (+1.28%)
CGC   33.80 (-4.11%)
GE   13.42 (+3.39%)
MU   90.62 (-0.52%)
NIO   42.90 (-0.90%)
AMD   82.44 (-2.01%)
T   28.51 (+1.03%)
F   12.27 (-2.23%)
ACB   10.59 (-3.99%)
DIS   194.13 (+0.10%)
BA   232.12 (+4.02%)
NFLX   528.02 (-3.61%)
PFE   34.00 (+1.46%)
Log in
NASDAQ:CODX

Co-Diagnostics Stock Forecast, Price & News

$14.36
+0.47 (+3.38 %)
(As of 03/3/2021 12:32 PM ET)
Add
Compare
Today's Range
$13.80
Now: $14.36
$14.59
50-Day Range
$10.07
MA: $14.13
$19.21
52-Week Range
$5.57
Now: $14.36
$30.99
Volume23,341 shs
Average Volume1.77 million shs
Market Capitalization$405.94 million
P/E Ratio17.73
Dividend YieldN/A
Beta-3.3
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.
Co-Diagnostics logo

Headlines

Co-Diagnostics Names New CFO and CSO
February 24, 2021 |  finance.yahoo.com
Co-Diagnostics - Seeking Alpha
February 23, 2021 |  seekingalpha.com
92 Biggest Movers From Yesterday - Benzinga
February 10, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CODX
CUSIPN/A
Phone801-438-1036
Employees39
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$220,000.00
Book Value$0.10 per share

Profitability

Net Income$-6,200,000.00

Miscellaneous

Market Cap$405.94 million
Next Earnings Date3/30/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.68 out of 5 stars

Medical Sector

241st out of 1,969 stocks

Surgical & Medical Instruments Industry

26th out of 169 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -
$14.36
+0.47 (+3.38 %)
(As of 03/3/2021 12:32 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CODX News and Ratings via Email

Sign-up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions

Is Co-Diagnostics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Co-Diagnostics stock.
View analyst ratings for Co-Diagnostics
or view top-rated stocks.

What stocks does MarketBeat like better than Co-Diagnostics?

Wall Street analysts have given Co-Diagnostics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Co-Diagnostics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Co-Diagnostics' next earnings date?

Co-Diagnostics is scheduled to release its next quarterly earnings announcement on Tuesday, March 30th 2021.
View our earnings forecast for Co-Diagnostics
.

How were Co-Diagnostics' earnings last quarter?

Co-Diagnostics, Inc. (NASDAQ:CODX) announced its earnings results on Sunday, November, 15th. The company reported $0.53 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.63 by $0.10. The business earned $21.82 million during the quarter, compared to analysts' expectations of $28 million. Co-Diagnostics had a trailing twelve-month return on equity of 93.48% and a net margin of 53.81%.
View Co-Diagnostics' earnings history
.

How has Co-Diagnostics' stock been impacted by Coronavirus (COVID-19)?

Co-Diagnostics' stock was trading at $13.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CODX stock has increased by 4.8% and is now trading at $13.82.
View which stocks have been most impacted by COVID-19
.

What guidance has Co-Diagnostics issued on next quarter's earnings?

Co-Diagnostics issued an update on its fourth quarter 2020 IntraDay earnings guidance on Wednesday, January, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $26.184-27.275 million, compared to the consensus revenue estimate of $24.99 million.

What price target have analysts set for CODX?

2 analysts have issued 12 month target prices for Co-Diagnostics' shares. Their forecasts range from $20.00 to $30.00. On average, they anticipate Co-Diagnostics' stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 80.9% from the stock's current price.
View analysts' price targets for Co-Diagnostics
or view top-rated stocks among Wall Street analysts.

Who are Co-Diagnostics' key executives?

Co-Diagnostics' management team includes the following people:
  • Mr. Dwight H. Egan, Chairman, CEO & Pres (Age 68, Pay $295k)
  • Dr. Brent C. Satterfield, Co-Founder & Chief Science Officer (Age 44, Pay $237.5k)
  • Mr. Reed L. Benson, CFO & Sec. (Age 73, Pay $215k)
  • Dr. Mayuranki Almaula, Sr. VP of Overseas Operations & Strategic Alliances
  • Mr. Cameron Gundry, Head of Commercialization LATAM/EUR

Who are some of Co-Diagnostics' key competitors?

What other stocks do shareholders of Co-Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Moderna (MRNA), Vaxart (VXRT), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), iBio (IBIO), Advanced Micro Devices (AMD), Pfizer (PFE) and Johnson & Johnson (JNJ).

When did Co-Diagnostics IPO?

(CODX) raised $9 million in an initial public offering (IPO) on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO.

What is Co-Diagnostics' stock symbol?

Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."

Who are Co-Diagnostics' major shareholders?

Co-Diagnostics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.80%), Nuveen Asset Management LLC (2.45%), Northern Trust Corp (1.08%), Bank Julius Baer & Co. Ltd Zurich (0.61%), Principal Financial Group Inc. (0.53%) and Bank of New York Mellon Corp (0.53%). Company insiders that own Co-Diagnostics stock include Dwight H Egan, Eugene Durenard, Reed L Benson and Richard S Serbin.
View institutional ownership trends for Co-Diagnostics
.

Which institutional investors are selling Co-Diagnostics stock?

CODX stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Schroder Investment Management Group, IFG Advisory LLC, ExodusPoint Capital Management LP, Creative Planning, JPMorgan Chase & Co., Barclays PLC, and ETF Managers Group LLC. Company insiders that have sold Co-Diagnostics company stock in the last year include Dwight H Egan, Eugene Durenard, Reed L Benson, and Richard S Serbin.
View insider buying and selling activity for Co-Diagnostics
or view top insider-selling stocks.

Which institutional investors are buying Co-Diagnostics stock?

CODX stock was purchased by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Bank Julius Baer & Co. Ltd Zurich, BlackRock Inc., Price T Rowe Associates Inc. MD, Bank of New York Mellon Corp, Nuveen Asset Management LLC, Summit Wealth & Retirement Planning Inc., and Panagora Asset Management Inc..
View insider buying and selling activity for Co-Diagnostics
or or view top insider-buying stocks.

How do I buy shares of Co-Diagnostics?

Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Co-Diagnostics' stock price today?

One share of CODX stock can currently be purchased for approximately $13.82.

How much money does Co-Diagnostics make?

Co-Diagnostics has a market capitalization of $390.68 million and generates $220,000.00 in revenue each year. The company earns $-6,200,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

How many employees does Co-Diagnostics have?

Co-Diagnostics employs 39 workers across the globe.

What is Co-Diagnostics' official website?

The official website for Co-Diagnostics is www.codiagnostics.com.

Where are Co-Diagnostics' headquarters?

Co-Diagnostics is headquartered at 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84124.

How can I contact Co-Diagnostics?

Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84124. The company can be reached via phone at 801-438-1036 or via email at [email protected]


This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.